We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer/Oncology
-
1. Blood cleansing as immunotherapy: testing a novel cancer vaccine strategy
- Prof. Raymond Goodrich
-
3. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
4. CAR-T and TCR-T cellular immunotherapies in oncology
- Prof. Dr. Sebastian Kobold
-
5. Precision cancer medicine: development and future
- Prof. Maurie Markman
-
6. Pediatric cancer testing
- Prof. Joshua Schiffman
- Neurology/Neuroscience
-
7. Risdiplam for prenatal therapy of spinal muscular atrophy
- Dr. Richard Finkel
-
10. PANDAS: a potential link between group A streptococcal infections and neurological disorders
- Prof. P. Patrick Cleary
-
11. Characterizing barriers to care in migraine
- Prof. Dawn C. Buse
- Cardiovascular
-
12. Hypertrophic cardiomyopathy: therapies and treatments
- Prof. Srihari Naidu
- Respiratory Diseases
-
14. Predicting asthma exacerbations using machine learning models
- Dr. Nestor Molfino
- Immunology & Inflammation
-
15. Antiphospholipid syndrome and Lupus
- Prof. Graham Hughes
-
16. Opposition to vaccination: a transatlantic discussion
- Prof. Jonathan Temte
- Infectious Diseases/Microbiology
-
17. Combating the HIV epidemic
- Prof. William Blattner
-
18. Monkeypox: etiopathogenesis, prevention, and treatments
- Dr. Dennis Hruby
- Clinical Practice
-
19. Medical science liaisons (MSLs): who they are, what they do, and the role of The MSL Society- Dr. Samuel Dyer
-
21. Prescribing medications to children - a GP’s view
- Dr. Amanda Simmons
-
22. MAPS: the business of medical affairs
- Dr. Danie du Plessis
-
23. Kidney xenotransplantation
- Dr. Douglas J. Anderson
-
24. Epigenetic pharmaceuticals used in the clinic
- Dr. Thomas A. Paul
-
25. Elective caesarean sections from an evolutionary perspective
- Prof. Wenda Trevathan
- Genetics & Epigenetics
-
26. First-in-human gene therapy clinical trial: insights from the ECUR-506 phase 1/2 trial- Dr. Julien Baruteau
Topics Covered
- Spinal muscular atrophy (SMA)
- Prenatal therapy
- Fetal medicine
- Risdiplam
- SMN2 splicing modulation
- Genetic disorders
- Pediatric neurology
- Translational medicine
- Rare diseases
- In utero treatment
Biography
Dr. Richard S. Finkel is a renowned pediatric neurologist and expert in neuromuscular disorders, including spinal muscular atrophy (SMA) and Duchenne muscular dystrophy. He is Director of the Center for Experimental Neurotherapeutics at St. Jude Children’s Research Hospital and has played a pioneering role in the development of breakthrough therapies for SMA. Dr. Finkel is internationally recognized for his contributions to pediatric neurology and translational research.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Finkel, R. (2026, September 30). Risdiplam for prenatal therapy of spinal muscular atrophy [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 19, 2026, from https://doi.org/10.69645/CUNA9583.Export Citation (RIS)
Publication History
- Published on September 30, 2026
Financial Disclosures
- Dr. Richard Finkel has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Neuroscience
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: We're
joined today by
Dr. Richard Finkel from St.
Jude Children's Hospital,
who recently
published a report in
the New England
Journal of Medicine,
detailing the first
prenatal use of risdiplam,
a medication used to treat
spinal muscular atrophy, or SMA.
Prof. Finkel, thank you so
much for joining us today.
Dr. Finkel: It's my
pleasure. Thank you for
this opportunity to expand
upon our case report.
Interviewer: Can you
start by providing
our audience with a
summary of your report?
Dr. Finkel: Certainly.
This was an opportunity
that fell in my lap more
or less, because parents
reached out to me
for a consultation,
and I did what's called
a telemedicine
consult more remotely
because the family lives a
bit away from my hospital.
They already were well
informed about SMA.
Unfortunately, they
had a prior baby
with a more severe form
of SMA called Type I,
who was born before any of
the three currently
available treatments
were available for their child,
and that child
passed in infancy.
They were well aware of
the serious nature of SMA,
and when the parents found that
they were pregnant
with another child,
they elected to undergo
an amniocentesis to see
whether that fetus
was affected or not.
In fact, it was, unfortunately.
But that led them to consider
different treatment options.
They were already aware that
there are these
three approved drugs
by the regulatory
agencies both in
the US and in Europe and
many other countries now,
and those are available
for treatment
shortly after birth.
Those are typically given
to babies in the first
few weeks of life.
Those babies are identified by